University of Minnesota. Driven to Discover.
The new drug is a 'modernized' version of tetracycline, designed to address antibiotic resistance, but its clinical role isn't yet clear.
About 61% of kids in children's hospitals got guideline-concordant therapy, compared with only 27% in non-children's hospitals.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.